Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Assessing Eli Lilly's Performance Against Competitors In Pharmaceuticals Industry November 05, 2024 — 10:00 am EST Written by Benzinga Insights for Benzinga -> ...

Eli Lilly & Co. LLY shares have nosedived 12.5% month-to-date through Nov. 19, putting the stock on track for its worst monthly performance since February 2009, when it tumbled 20.2%.

Eli Lilly (NYSE: LLY) stock has soared 90% over the past year, a huge gain for a pharmaceutical company. ... As a result, Lilly's earnings and stock performance have surged.

Eli Lilly (LLY) is experiencing a banner year, as its stock price has reached new all-time highs in June. The surge comes on the heels of a series of positive developments for the pharmaceutical ...

However, when looking at the fundamental performance of these two, I don’t see many reasons for the stock outperformance of Eli Lilly. At best, we can call it a head-to-head race.

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk .

Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating today. Geoff Meacham has given his Buy rating due to a combination of factors ...